Literature DB >> 9530377

Helical CT angiography of living renal donors: comparison with 3D Fourier transformation phase contrast MRA.

K Tsuda1, T Murakami, T Kim, Y Narumi, S Takahashi, K Tomoda, S Takahara, A Okuyama, H Oi, H Nakamura.   

Abstract

PURPOSE: The purpose of this study was to determine whether helical CT angiography (CTA) or MR angiography (MRA) is the optimal method to use as a preoperative examination for anatomic arterial assessment of living renal donors.
METHOD: Eighteen candidates to be renal donors underwent helical CTA, 3D Fourier transformation phase contrast (3D-FT-PC) MRA, and digital subtraction angiography (DSA). The CTA and MRA were interpreted separately by three readers independently, and these results were correlated with the findings of DSA.
RESULTS: DSA showed nine accessory renal arteries and 10 prehilar branches. CTA revealed seven or eight accessory renal arteries. MRA showed six or seven accessory arteries. Of 10 prehilar branches, 7-9 branches were detected with CTA and 5-8 branches with MRA.
CONCLUSION: Helical CTA is superior to 3D-FT-PC MRA for evaluating the arterial anatomy of living renal donors.

Mesh:

Substances:

Year:  1998        PMID: 9530377     DOI: 10.1097/00004728-199803000-00005

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  2 in total

1.  [Analysis of 64-row multidetector CT images for preoperative angiographic evaluation of potential living kidney donors].

Authors:  D Blondin; K Andersen; P Kroepil; M Cohnen; U Mödder; W Sandmann; K Ivens; G Jung
Journal:  Radiologe       Date:  2008-07       Impact factor: 0.635

2.  Pre-operative assessment of living renal transplant donors with state-of-the-art imaging modalities: computed tomography angiography versus magnetic resonance angiography in 118 patients.

Authors:  F Engelken; F Friedersdorff; T F Fuller; A Magheli; K Budde; F Halleck; S Deger; L Liefeldt; B Hamm; M Giessing; G Diederichs
Journal:  World J Urol       Date:  2013-01-08       Impact factor: 4.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.